Skip to main content
Clinical Trials/NCT04826991
NCT04826991Active, not recruitingNot Applicable

Wells and Enteric Disease Transmission - A Randomized Trial of Children Supplied Drinking Water From Private Wells (WET-Trial)

Temple University1 site in 1 country908 target enrollmentStarted: July 1, 2021Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Active, not recruiting
Enrollment
908
Locations
1
Primary Endpoint
Incident gastrointestinal illness

Study Overview

Brief Summary

Approximately 40 million people in the US are served by private, and frequently untreated, wells. Our best estimate is that 1.3 million cases of gastrointestinal illnesses (GI) per year are attributed to consuming water from untreated private wells in the US, but in reality, there are no robust epidemiological data that can be used to estimate cases of GI attributable to these sources. We propose the first randomized controlled trial (RCT) to estimate the burden of GI associated with private well water. We will test if household treatment of private well water by ultraviolet light (UV) vs. sham (inactive UV device) decreases the incidence of GI in children under 5. We will also examine the presence of viral, bacterial, and protozoan pathogens in stool and well water from participants. These data will fill a knowledge gap on sporadic GI associated with federally-unregulated private water supplies in the US.

Detailed Description

Investigators will conduct a triple-blinded randomized controlled trial of a whole-home UV water treatment device in southeastern Pennsylvania. Participating families will be randomized to receive an active UV device or a sham (inactive) UV device. Following the installation of the device, participants will be followed for one year. During that year, participants will respond to weekly text messages to report the presence of symptoms associated with gastrointestinal and respiratory illness in their children. Upon reporting symptoms, participants will complete an illness questionnaire on details regarding the illness and other potential exposure events. A subset of participants will submit groundwater samples as well as stool and saliva samples from their children. Water and stool samples will be analyzed for common waterborne pathogens. Saliva samples will be analyzed for immunoconversions to common waterborne pathogens (exploratory aim).

Under the guidance of an interdisciplinary advisory committee we will execute the following aims:

Aim 1- Quantify the incidence rate of endemic childhood GI associated with consuming untreated private well water and compare that to the incidence rate of consuming well water treated by UV.

Aim 1a- Construct a Quantitative Microbial Risk Assessment (QMRA) using water quality data we collect to estimate the risk of childhood GI associated with consuming untreated private well water and compare the incidence from the risk model to the incidence we calculate in Aim 1.

Aim 2- Identify, quantify and compare viral, bacterial and protozoan pathogens in stool of children consuming UV treated or untreated (sham) private well water (including both asymptomatic and symptomatic cases).

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Prevention
Masking
Triple (Participant, Investigator, Outcomes Assessor)

Masking Description

Participants, device installers, investigators, and outcomes assessor will all be blinded.

Eligibility Criteria

Ages
6 Months to 59 Months (Child)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • •Child resides in Adams, Berks, Bucks, Carbon, Chester, Columbia, Cumberland, Dauphin, Delaware, Lackawanna, Lancaster, Lebanon, Lehigh, Luzerne, Monroe, Montgomery, Montour, Northumberland, Northampton, Perry, Pike, Schuylkill, Wayne, Wyoming, and York county in Pennsylvania and all counties in New Jersey.
  • •Household is served by a private well
  • •Participant child is under the age of 5 (under 4 at time of enrollment), who is a full-time resident of the home and drinks untreated well water
  • •Parent/guardian has access to a phone with texting capabilities

Exclusion Criteria

  • •Child participant is immunocompromised
  • •Child participant has a chronic gastrointestinal condition
  • •Child takes daily oral steroids
  • •Household treats water for microbiological contamination before consumption
  • •Child exclusively drinks bottled water

Arms & Interventions

Active UV Device

Active Comparator

A household water treatment device with a lamp emitting germicidal UV. The device will be operated at 50 millijoule per square centimeter to treat >99.9% of all bacteria, protozoa, and most viruses in water supplies.

Intervention: Active UV Device (Device)

Inactive UV Device

Sham Comparator

A household water treatment device with a lamp not emitting germicidal UV but still emitting light (appears identical to the active UV device).

Intervention: Inactive UV Device (Device)

Outcomes

Primary Outcomes

Incident gastrointestinal illness

Time Frame: 12 months

The investigators will collect data on the presence of gastrointestinal illness symptoms through weekly text messages. Households that report symptoms through text messages will be directed to an online illness questionnaire to characterize the symptoms (type, incidence, severity, duration, etc.), as well as relevant exposure information such as recent travel, exposure to ill persons, etc. Incident gastrointestinal illness (GI) is defined by the reporting of a minimum of three episodes of diarrhea or vomiting in a 24 hour period. Each illness will be considered distinct when separated by ≥ 6 symptom-free days.

Secondary Outcomes

  • Acute respiratory infection(12 months)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Heather Murphy

Adjunct Associate Research Professor

Temple University

Study Sites (1)

Loading locations...

Similar Trials

Active, not recruiting
Phase 1
A randomized, open-label, national in patients with newly-diagnosed, symptomatic multiple myeloma.Multiple Myeloma
EUCTR2014-000554-10-ESFundación PETHEMA316
Active, not recruiting
Phase 1
Open label treatment extension study with SAR245408 or SAR245409 as a monotherapy or as a combination regimeeoplasm malignantMedDRA version: 14.1Level: PTClassification code 10028997Term: Neoplasm malignantSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2011-006140-78-FRSanofi-aventis recherche & développement150
Active, not recruiting
Not Applicable
Open label treatment extension study with SAR245408 or SAR245409 as a monotherapy or as a combination regimeeoplasm malignantMedDRA version: 17.0Level: PTClassification code 10028997Term: Neoplasm malignantSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2011-006140-78-BESanofi-aventis recherche & développement150
Active, not recruiting
Phase 1
Open label treatment extension study with SAR245408 or SAR245409 as a monotherapy or as a combination regimeeoplasm malignantMedDRA version: 14.1Level: PTClassification code 10028997Term: Neoplasm malignantSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2011-006140-78-ESSanofi-aventis recherche & développement150
Recruiting
Phase 4
Registry-based Study of Enzalutamide vs Abiraterone assessing cognitive function in ELderly patients with Metastatic Castration-Resistant Prostate CancerMetastatic Castration-Resistant Prostate CancerCognitive declineCancer - ProstateMental Health - DepressionDepression
ACTRN12620000463976Walter and Eliza Hall Institute for Medical Research200